Abstract: Stevia varieties with a high content of RebM, are disclosed Further provided are methods for producing Stevia plants having a high RebM content by negatively regulating certain genes selecting the resulting plants, and breeding with such plants to confer such desirable Reb M phenotypes to plant progeny.

Abstract: The present disclosure provides compositions and methods for producing transgenic banana plants that exhibit increased resistance to Fusarium oxysporum f.sp. cubense Tropical Race 4 (TR4), and the banana plants and bananas so produced.

Abstract: The present disclosure provides compositions and methods for producing transgenic plants and other organisms that exhibit increased production of mogroside compounds, in particular mogroside V, and the mogroside compounds, plants and plant parts so produced.

Abstract: Provided herein are methods for improving various traits in plants, such as in Vanilla sp. plants, by genetically-modifying the genome of plants, introducing heterologous sequences into the plants, or breeding plants with selected alleles. Such traits that can be improved by the methods and compositions of the present invention include an increase in levels of vanillin or one or more precursors thereof, reducing dehiscence, reducing the size of a rostellum or eliminating its presence, and increasing fungal resistance. Also disclosed herein are genetically-modified plants, extract from such plants or plant parts thereof, and methods of producing such plants or progeny thereof.

Abstract: The present disclosure presents a solution to producing mogrosides and mogroside-based sweeteners having low or no calorie. By using recombinant gene and plant transformation techniques, non-native genes encoding mogroside pathway enzymes are introduced/implemented into the genome of a plant hereby forming a transgenic plant, wherein the plant by the native genome thereof prior to transformation may not produce mogrosides naturally. Such transgenic plant and a progeny thereof are enabled to produce non-native mogrol precursors, mogrol, mogrosides, and/or metabolites or derivatives thereof.

Abstract: Stevia varieties with a high content of RebM, are disclosed Further provided are methods for producing Stevia plants having a high RebM content by negatively regulating certain genes selecting the resulting plants, and breeding with such plants to confer such desirable Reb M phenotypes to plant progeny.

Abstract: Provided herein are methods for increasing the level of mogrosides in plants, such as in Cucurbitaceae family plants (e.g., in watermelon), by genetically-modifying such plants to modulate the expression of endogenous mogroside pathway genes. Also disclosed herein are plants with increased levels of mogrosides, extract (e.g., sweetener) from such plants, parts (e.g., juice, seed, pulp, etc.) from such plants, and methods of producing such plants.

Abstract: Stevia varieties with a high content of RebM, are disclosed Further provided are methods for producing Stevia plants having a high RebM content by negatively regulating certain genes selecting the resulting plants, and breeding with such plants to confer such desirable Reb M phenotypes to plant progeny.

Abstract: Stevia varieties with a high content of RebM, are disclosed Further provided are methods for producing Stevia plants having a high RebM content by negatively regulating certain genes selecting the resulting plants, and breeding with such plants to confer such desirable Reb M phenotypes to plant progeny.

Abstract: Stevia varieties with a high content of RebM, are disclosed Further provided are methods for producing Stevia plants having a high RebM content by negatively regulating certain genes selecting the resulting plants, and breeding with such plants to confer such desirable Reb M phenotypes to plant progeny.

Abstract: This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.

Abstract: This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.

Abstract: This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.